logo
Plus   Neg
Share
Email

Aerpio Pharma: TIME-2b Study With AKB-9778 Fails To Meet Primary Endpoint

Aerpio Pharmaceuticals, Inc. (ARPO) announced top-line results from the company's TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of lead candidate, AKB-9778, for patients with moderate to severe non-proliferative diabetic retinopathy. The company said the administration of AKB-9778 twice daily did not meet the study's primary endpoint of the percentage of patients with an improvement of two or more steps in the study eye diabetic retinopathy severity score compared to placebo.

AKB-9778 did show encouraging data in a number of prespecified, key secondary endpoints, consistent with the observations in the prior Phase 2a trial, the company noted. AKB-9778 was found to be safe and well-tolerated in the patient population through 48 weeks of twice-daily dosing.

"While we are disappointed in the primary endpoint results of this study, we are nevertheless encouraged by the fact that several other promising findings observed in our prior 3-month Phase 2a trial have been prospectively confirmed in this 1-year trial. We and our clinical advisors believe that collectively these data support a potentially important role of the Tie2 pathway for the treatment of diabetic complications, as well as for open angle glaucoma. After a full analysis of the study data, we plan to provide an update on the status of the NPDR program," said Stephen Hoffman, CEO of Aerpio.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Luckin Coffee Inc., Starbucks Corp.'s biggest rival in China, filed for an Initial Public Offering in the U.S. In a filing with the Securities and Exchange Commission, the China-based coffee chain said it has applied for listing its American Depositary Shares or ADSs on the Nasdaq under the symbol "LK" and also set a placeholder amount of $100 million. Micro-blogging site Twitter Inc. (TWTR) Tuesday reported a surge in its first-quarter profit. Both earnings and revenues beat analysts' estimates, sending shares up by 6 percent in the pre-market trading. But, Twitter's average monthly active users or MAU figure declined from last year. Verizon Communications Inc. on Tuesday reported a nearly 11 percent increase in profit for the first quarter from last year on higher wireless revenues and flat expenses. Adjusted earnings per share for the quarter beat analysts' estimates, while revenues were in-line with expectations. Looking ahead, the company raised its adjusted earnings outlook for fiscal 2019.
Follow RTT